147 results
8-K
NAOV
NanoVibronix Inc
16 May 24
NanoVibronix Issues Letter to Stockholders
4:05pm
Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement or amend the materials
8-K
NAOV
NanoVibronix Inc
9 Apr 24
NanoVibronix Issues Letter to Stockholders
4:05pm
the materials attached hereto.
The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished pursuant
8-K
r83ihjds1 r3
28 Mar 24
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
9:09am
DEFA14A
c7detsu5bwt81z6t8
29 Nov 23
Additional proxy soliciting materials
8:43pm
8-K
tv68we
28 Nov 23
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
9:00am
8-K
7ql5 efu4dhi
14 Nov 23
NanoVibronix Issues Letter to Shareholders
12:00am
8-K
4n45wx0regl umn
7 Nov 23
Receives Stocking Order from U.K. Distribution Partner in Anticipation of Increasing Demand
8:30am
8-K
ungllx7otroq0c
27 Sep 23
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
8:00am
D
l4037mmi6hujdbm
13 Sep 23
$13.55 mm in equity / options / securities to be acquired, sold $13.55 mm, 1 investor
4:45pm
8-K
p9feqvc7
6 Sep 23
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
8:30am
8-K
EX-10.1
z9w9e
1 Sep 23
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:30pm
8-K
EX-10.2
0cbuy40
1 Sep 23
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:30pm
8-K
3a5qg1gr
30 Aug 23
NanoVibronix Cites Positive Results from Independent Testing of UroShield
8:30am
8-K
260rv1v k96gd0j
29 Aug 23
Regulation FD Disclosure
4:05pm